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Breast cancer remains a leading cause of morbidity and mortality in women mainly because of the propensity of primary
breast tumors to metastasize. Growing experimental evidence suggests that cancer stem cells (CSCs) may contribute to tumor
progression and metastasis spread. However, despite the tremendous clinical potential of such cells and their possible therapeutic
management, the real nature of CSCs remains to be elucidated. Starting from what is currently known about normal mammary
stem/progenitor cells, to better deﬁne the cell that originates a tumor or is responsible for metastatic spread, this review will
discuss experimental evidence of breast cancer stem cells and speculate about the clinical importance and implications of their
evaluation.
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1.Introduction
Despite signiﬁcant advances in diagnosis and clinical man-
agement, breast cancer remains a leading cause of morbidity
and mortality in women [1], mainly owing to the propensity
of primary breast tumors to metastasize to regional and
distant sites suchas lymph nodes, lung, liver, bone, and brain
[2].Whentheprimarytumorisdetectedandremovedbefore
metastasis occurs, prognosis could be good and the chance
of disease-free survival is high. However, if cancer cells have
already begun to disseminate from the primary tumor and
spread to other organs, current therapeutic strategies largely
dependontheuseofsystemiccytotoxicdrugsthatfrequently
result in severe side eﬀects on the patient and, in many cases,
do not yield long-term success.
This clinical scenario is further complicated by the fact
that invasive breast cancers exhibit a wide range of mor-
phological types, molecular proﬁles, and clinical behaviors.
Not only there is a large variation in the nature of cell types
between cancers, but even within a single tumor a signiﬁcant
heterogeneity in phenotype and genotype can be observed
[3]. Based on growth patterns and cytological characteristics
of the tumor cells, invasive breast cancers are categorized by
the World Health Organization into 18 diﬀerent histological
subtypes, each of them associated with a diverse clinical
behavior. In addition to morphology, invasive breast cancers
canalsobeclassiﬁedaccordingtotheirproliferativepotential
(evaluated, e.g., by Ki67 expression) or the presence of such
biological factors as hormone receptors (estrogen [ER] and
progesterone [PgR]) or HER2/neu overexpression that are
currently used in clinical practice to predict the prognosis
and the response/resistance to cytotoxic and/or hormonal
therapy [4–6].
Understanding the molecular causes of such a hetero-
geneity is therefore of paramount importance not only
for the development of new therapeutic approaches, but
also for a better knowledge of the biological bases of
breast tumorigenesis and metastatic spread. To address these
questions, over the past decade, scientists have used inno-
vative technical strategies and approached new intriguing
directions aimed to deﬁne the genetic and epigenetic proﬁle
ofthesingletumorandtobetterdeﬁnethecellthatoriginates
a tumor or is responsible for metastatic spread. In particular,
investigators focused their attention on the hypothesis that2 Journal of Oncology
breast cancer may be a stem cell disease, arising from
tissue stem/progenitor cells or driven by cells with stem-cell
properties [7].
2. Isolation and Characterization of Mammary
Stem/Progenitor Cells
In the adult, cell loss, associated with the physiological tissue
turnover, is compensated by the activity of speciﬁc cells,
termed stem cells, which are so deﬁned by their ability
to self-renew and to generate the entire repertoire of the
diﬀerentiated cells composing a given tissue. Since 1983,
the existence of such stem cells has also been postulated
in the mammary gland to explain the cellular dynamics
underlying morphological changes throughout a woman’s
life, particularly during and after pregnancy [8].
In general, the identiﬁcation and puriﬁcation of normal
stem cells are diﬃcult tasks because of the paucity of stem
cells in the tissue of origin and to the lack of stemness-
speciﬁc morphologic traits. Hence, animal models have been
used, and the murine model, in particular, has supplied
relevant data to improve our understanding of the cell
biology of the mammary gland and to clarify the presence
of stem/progenitor cell and diﬀerentiated cell compartments
in the mammary gland [9, 10]. However, the information
obtained from mice cannot be directly applied to humans
(as in the case of murine exclusive cell surface markers) or
may not be promptly translated to humans, as known in
the hematopoietic ﬁeld, where an opposite surface-antigen
proﬁlewasobservedinhumans(CD34+CD38
−)withr espect
to mice (CD34
−CD38+). Several in vitro strategies have thus
been developed to isolate and characterize human mammary
stem/progenitor cells, based on the diﬀerential expression of
some cell surface markers, the formation of mammospheres,
and the use of ﬂuorescent dyes.
2.1. Cell Surface Markers. The ﬁrst experimental evidence
of the existence of human mammary stem/progenitor cells
was obtained by the in vitro isolation of multipotent
epithelial cells, from normal human adult breast, accord-
ing to their diﬀerent expression of MUC-1 glycoprotein,
CALLA/CD10, and epithelial-speciﬁc antigen (ESA). Using
these markers, two epithelial-cell progenitor populations
were distinguished, corresponding to the two components
of normal mammary gland (myoepithelial cells, forming the
basal layer of ducts, and epithelial cells, lining the lumen
of ducts and forming the alveoli) [11–13]. Subsequently,
Gudjonsson et al. [13], starting from the previous ﬁndings
[14],providedinvivoevidenceofthemorphogenicpotential
of the MUC-1−/ESA+ subpopulation, inoculating these cells
subcutaneously in nude mice after pre-embedding them in a
mixture of collagen gel and matrigel.
2.2. Mammosphere Formation. To identify a human mam-
mary stem/progenitor-cell subpopulation, Dontu et al. [15]
adopted a strategy similar to that employed for primary
neural cells and based on the formation of ﬂoating spherical
colonies used to deﬁne and measure stem cell-like behavior.
In fact, contrary to the dogma that epithelial cell survival
is anchorage-dependent, single cell suspensions of human
mammary epithelial cells, obtained by mechanic/enzymatic
dissociation, surprisingly survived in suspension and gener-
ated ﬂoating spherical colonies, termed nonadherent mam-
mospheres [15]. The mammospheres contained numerous
undiﬀerentiated cells that, once isolated from the cluster,
were able to generate new multilineage colonies, when
culturedunderdiﬀerentiatingconditions,and,in3Dculture,
to reconstitute a functional mammary gland. However, the
intrinsic dynamics of such cytospheres, as conventionally
assayed, introduces several confounders, as reported in a
recent paper by Singec et al. [16] who underlined the need
to use more accurate conditions for assessing the clonality,
number, and fate of stem cells. Although sphere formation
may represent a useful culturing tool, it is not speciﬁc to
stem cell characterization; any dividing cell from virtually
any tissue will form ﬂoating cell clusters, when cultured in a
serum-free medium and on a nonadherent substrate, owing
to a predominant intercellular adhesiveness. Spontaneous
sphere fusion may occur in normal as well as in neoplastic
sphere cultures. Furthermore, in agreement with Singec et al.
[16], we have observed that the mammospheres, supposedly
rich in multilineage progenitors, have a very short life span
(about 3-4 weeks), making it diﬃcult to deﬁne the cells
composingthemasrealmammarystemcells,whicharelong-
lived by deﬁnition. On account of all these criticisms, this
experimental approach, based on the ability of the supposed
mammary stem cells to generate clonal mammospheres
under anchorage-independent culture conditions, has been
deﬁned “a surrogate stem cell assay” [17].
2.3. Fluorescence Methods. To overcome the challenge repre-
sented by the limited availability of stemness markers and to
take advantage of the ability of stem cells to extrude dyes, for
example, Hoechst-33342 DNA-binding dye or rhodamine
because the overexpression of some membrane transporter
proteins, such as P-glycoproteins or breast cancer resistance
proteins (BCRPs) [18, 19], ﬂuorescent dyes have been used
to identify and isolate by ﬂow cytometry a small fraction of
cells supposed to be stem progenitors [20]. This cell fraction,
which amounts to around 0.2% of the total population, has
been called side population (SP).
However, several criticisms to such a sorting technique
have been raised in the recent years principally concerning
the toxicity of dyes used in the analysis [21] and the
high assay variability associated with technical modiﬁcations
required for each cell population under study; these lim-
itations hamper the comparison of results obtained from
diﬀerent studies and aﬀect cell selection for in vitro and
in vivo growth experiments. In addition, recent ﬁndings
from two teratocarcinoma cell lines indicate that Hoechst
treatment, as performed during staining for SP analysis,
can aﬀect cell diﬀerentiation, suggesting other potential
complications in the interpretation of data [22].
Recently, another approach, based on aldehyde dehydro-
genase (ALDH) activity, has been proposed as a promising
alternative toidentify andcharacterizethehuman mammary
stem/progenitor component in the mammary gland [23].Journal of Oncology 3
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Figure 1: Models of heterogeneity in solid cancer cells.( a )T h eclonal evolution model assumes that every cell in a tumor is potentially tumor-
initiating.Progressionisgovernedbyrarestochastic eventsoperatinginallcells.Cellswithmutations(yellow)thatacquiregrowthadvantage
will dominate over all other cells in the tumor and will originate a new clone containing cells characterized by a diﬀerent phenotype and
having diﬀerent proliferative potentials; in a clonogenicity or tumorigenicity assay, some of these cells (blue) would have a low probability
of exhibiting this potential. (b) The cancer stem cell model states that a particular subset of tumor cells with stem cell-like properties,
called “cancer stem cell” (CSC) (pink), drives tumor initiation, progression, and recurrence. CSCs are able to self-renew indeﬁnitely and
to diﬀerentiate, leading to the production of all cell types (blue) that make up the rest of the tumor. In clonogenic assays, CSCs have the
potential to proliferate extensively and can form new tumors on transplantation.
ALDH, a detoxifying enzyme responsible for the oxidation
of intracellular aldehydes, is a putative candidate marker of
stemness, since it is highly expressed in hematopoietic and
neuronal stem/progenitor cells. Its presence can be evaluated
by ALDEFLUOR kit: brightly ﬂuorescent ALDH-expressing
cells are easily detected by ﬂow cytometry in the green
ﬂuorescence channel. Using such an approach, Ginestier et
al. [23] showed that ALDH-positive cells formed mammo-
spheres with high eﬃciency (10 ± 3.5%) when put into 96-
well plates (1cell/well), and displayed stem-like properties
in terms of bilineage diﬀerentiation in vitro and outgrowth
potential when inoculated in the mammary fat pad of
humanizedmice.However,eventhoughtheﬁndingsindicate
thatonlyALDH-positivecellshadphenotypicandfunctional
characteristics of mammary stem cells, immunostaining of
tissue sections using a monoclonal antibody against the ﬁrst
isoform of ALDH (ALDH1) did not detect any overlapping
expression of several markers (e.g., CK5/6 and CK14), pre-
viously associated with undiﬀerentiated mammary epithelial
cells, probably owing to the scarcity of this population.
Analysis performed on mammosphere sections have shown
that ALDH1-positive cells represented approximately 5% of
the total cell population and expressed CK5/6 or CK14, sup-
porting the hypothesis that ALDH1-positive cells represent
the stem/progenitor population [13, 15].
Unfortunately, as highlighted by these inconclusive res-
ults, the eﬀorts to purify adult stem cells from the human
mammary gland have so far been hampered, on the one
hand, by the lack of cell surface markers speciﬁc to undiﬀer-
entiated or diﬀerentiated mammary cells and, on the other
hand, by the lack of suitable in vivo assays for testing stem
cellproperties,withtheconsequencethathumanbreaststem
cells have not yet been extensively characterized.
3. Cancer PropagationModels
To explain why not every cell within a tumor is capable of
maintaining and/or reinitiating tumor growth, two models
of heterogeneity in solid cancer have been proposed: the
clonal evolution model (Figure 1(a)) and the cancer stem cell
(CSC) model (Figure 1(b))[ 24–26].
The two main aspects of the clonal evolution model, ﬁrst
proposed by Nowell in 1976 [27], are (1) diversity within
the tumor due to genetic instability and (2) selection of the
cells with the most advantageous phenotype. In this respect,
stem or diﬀerentiated cell characteristics (including self-
renewing capacity) are just simple phenotypes and, as such,
can change. According to this model, any cancer cell can
potentially become invasive and cause metastasis or become
resistant to therapies and cause recurrence.
The cancerstem cell (CSC) model (Figure 1(b)) states that
a particular subset of tumor cells with stem cell-like proper-
ties, called “cancer stem cells”, drives tumor initiation, pro-
gression, and recurrence. Since CSCs are widely believed to
arise from normal stem or progenitor cells, the identiﬁcation
of stem cells in a tissue is of paramount importance to
understand how a tumor arises. By deﬁnition, CSCs have
the ability to self-renew indeﬁnitely and to diﬀerentiate,
which leads to the production of all cell types composing
a tumor, both tumorigenic and nontumorigenic cells. But
the latter lack the unlimited self-renewing capacity and
the ability to reproduce the phenotypically diverse cell4 Journal of Oncology
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Figure 2: Mixed model for the nature of sustained tumor growth. The tumor is originally driven by rare cells of one phenotype (CSC1,yellow),
which may have stem/progenitor cell origin and give rise to the tumor bulk by producing terminally diﬀerentiated cells (blue). Subsequent
mutations enhancing self-renewing capacity create a dominant subclone that is phenotypically diﬀerent (CSC2, green) and more aggressive.
If the CSC2 subclone does not display “stem-like” cell properties, such a subset will not be able to initiate tumors with a high frequency [30].
populationsthatmakeupthetumorbulk[28,29].Therefore,
this model suggests that the presence of such rare tumor-
initiatingcells,intheheterogeneousmixofcellscomposinga
tumor, is essential for neoplastic progression and metastatic
spread [29, 30]. While the CSC model of carcinogenesis was
described in the context of systemic malignancies as long
ago as in the 1930s, only recently has it been extended to
solid tumors, and during the last decade, several studies have
provided evidence that CSCs may also exist in solid tumors
including brain [31], lung [32], prostate [33], colon [34],
liver [35], pancreas [36], and breast [37] carcinomas, as well
as melanoma [38].
In breast tumorigenesis, the CSC model also seems to be
supported by clinical observations indicating that, despite
the fact that breast cancer patients may have hundreds or
thousands of single disseminated cancer cells detectable in
their bloodstream, only a very small percentage of cells
progresses to form overt macroscopic metastases [39], and
that metastatic tumors tend to reproduce a heterogeneity
similar to the primary tumor [40] .S i n c eC S C sh a v eb e e n
supposed to be responsible for the chemo- and radioresis-
tance observed in several solid tumors [41, 42], the CSC
modelcouldexplainsuchaﬁndingwiththeabilityofCSCsto
escape cytotoxic drugs, via a high expression of speciﬁc drug
transporter proteins, and to resist radiotherapy by increasing
DNA repair activity.
Unfortunately, the deﬁnitive proof of the cellular origin
of CSCs—they may arise either from normal resident stem
cells within the tissue bearing the malignancy or from
transformed progenitor cells that acquire the stem cell ability
of self-renewal—remains elusive and is a topic of intense
debate as well as experimental investigation. In fact, if
these cells arise from normal stem cells, then cancer cells
could take advantage of the existing regulatory self-renewal
pathways of stem cells. On the other hand, if these cells
arise from mature, diﬀerentiated cells, multiple oncogenic
mutations, aﬀecting diﬀerentiation and self-renewal path-
ways are required for a cell to become tumorigenic and
metastatic [43, 44]. It can be argued that mature cells have
a very limited life span, and thus it is unlikely that all
the necessary mutations could occur during the relatively
short life of these cells. In contrast, the unlimited self-
renewing capacity of normal stem cells could enable them
to accumulate the necessary mutations, despite the apparent
paradox of the stem cell dogma, according to which a
stem cell maintains its DNA constant through symmetric
division [26, 45]. Thus, whereas the CSC model is highly
hierarchicalwithauniqueself-renewingcelltypeattheapex,
the clonal evolution model attributes much of the intratumor
variation to subclonal diﬀerences in mutational proﬁle and
implies that all cells, except the terminally diﬀerentiated
ones, may have self-renewal capacity. Nevertheless, clonal
evolution and CSC models share some aspects: in both, for
instance, the tumor arises from a single cell that has acquired
multiple mutations and has gained unlimited proliferative
potential. This suggests that tumor heterogeneity could be
explained by a new version of the clonal evolution model
that incorporates some features of the CSC hypothesis
[26].
A more intriguing model to explain the nature of sus-
tained tumor growth is now emerging from the CSC model.
According to this new model (Figure 2), tumors could origi-
nally be driven by rare CSCs (CSC1). Subsequent mutations,
enhancing self-renewing capacity, could create a dominant,
moreaggressivesubclone(CSC2),withaphenotypicalaspect
distinct from the original CSC. However, if the CSC2
subclone does not display “stem-like” properties, it should
not be able to initiate tumors with a high frequency [46].Journal of Oncology 5
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Figure 3: Metastatic evolution. Genetic and epigenetic mechanisms may cause the generation of a self-renewing metastatic cancer stem cell
subclone(mCSC,yellow), phenotypically diﬀerent fromtheCSCthatisdrivingtumorigenesis(pink).Throughaseriesof invasiveprocesses,
mCSC enters blood vessels and colonizes distant organs according to the seed and soil hypothesis. Blue cells represent bulk tumor cells [47].
Althoughmetastasisisthepredominantcauseoflethality
in breast cancer patients, metastatic spread is a highly
ineﬃcient process, since very few cells successfully colonize
distant sites. A possible explanation of this ineﬃciency is
provided by the CSC model, according to which genetic
and epigenetic mechanisms may generate, within the pri-
mary tumor, a self-renewing metastatic cancer stem cell
(mCSC) characterized by an immunophenotype diﬀerent
from the CSC that is driving tumorigenesis (Figure 3). This
is suggested by the observation that in metastatic sites,
some cell subpopulations with self-renewing features display
ac e l ls u r f a c em a r k e rp r o ﬁ l ed i ﬀerent from the CSC that
originated the primary tumor [47]. Through a series of
invasive processes, this new mCSC subclone could enter
blood vessels and colonize distant organs according to the
“seed and soil” hypothesis.
4. Isolation andCharacterization of Breast
Cancer Stem Cells
On account of accumulating evidence and according to the
CSC model that assumes a tissue stem/progenitor cell as
the origin of a tumor, some methods adopted to isolate
and cultivate normal mammary stem/progenitor cells have
also been applied to breast cancer tissue. However, there
may be biases, inherent in the techniques applied, that can
aﬀect experiment reproducibility. In fact, some technical
approaches, including the strong enzymatic digestion of
breast tissue necessary to disaggregate the connective tissue
surrounding the mammary gland, can cause damage to
cells or loss of some particular surface markers, hamper-
ing the identiﬁcation of unique markers for the putative
CSCs (authors’ unpublished data). Furthermore, since cell6 Journal of Oncology
recovery from solid tissue is usually low (rarely exceeding
10%), the samples obtained may not be representative of the
original lesion, owing to the rare presence of CSCs in the
tumor mass, actual CSCs may be lost, while other cells may
be mistakenly identiﬁed as CSCs [26].
The ﬁrst experimental clues about the existence of puta-
tive CSCs came from the observation that, even when using
immortalized cancer cell lines, large numbers of cells (in the
range 105–106) must be injected into experimental animals
to initiate a tumor and, in spite of that, only a very small
proportion of these cells will go on to form metastases [48].
Additional experimental studies showed that while early
steps in hematogenous metastasis (intravasation, survival,
arrest, and extravasation) can be remarkably eﬃcient, with
over 80% of cells successfully completing the metastatic
process at this point, only a small subset of these cells
(i.e., about 2%, depending on the experimental model) can
initiate growth as micrometastases and that an even smaller
subset (i.e., about 0.02%, depending on the experimental
model) is able to persist and grow into macroscopic tumors.
This suggests that the initial growth of micrometastases
represents the critical decision-making stage.
4.1. Surface Markers. After the identiﬁcation of stemness
speciﬁc markers in hematopoietic tumors, considerable
progress has also been made in the elucidation of the
biological properties of breast cancer stem cells. Al-Hajj et al.
[37] ﬁrst demonstrated the presence of a cell subpopulation
displaying stem cell properties, characterized by the cell
surface marker proﬁle CD44+/CD24low/lin−, in solid tissues
and in pleural eﬀusions of patients with advanced-stage
metastatic breast cancer. This phenotype displayed a 10- to
50-fold increase in the ability to form tumors in NOD/SCID
mice over unfractionated tumor cells. In addition, the
authors demonstrated that cells with such a speciﬁc cell
surface antigen proﬁle could successfully and eﬃciently grow
as tumor xenografts in immunodeﬁcient mice; the highest
capacity to form tumors was observed after injection of 200
cells with the ESA+/CD44+/CD24low/lin− phenotype.
However, the heterogeneous expression patterns of ESA,
CD44, or CD24, observed by FACS analysis in secondary
lesions,supportthehypothesisthattheCD44+/CD24low/lin−
proﬁle could be the marker of the putative breast CSC phe-
notype, since it recapitulates the heterogeneous complexity
of the tumors from which it has been isolated. Such a
hypothesis could be corroborated by a study in which Ince
et al. [49] observed the presence of two diﬀerent populations
of mammary epithelial cells in the tumor of a single patient.
Only one population was myoepithelial-like and was able
to give rise to tumors with heterogeneous histology and to
be tumorigenic when injected into mammary fat pads of
immunodeﬁcient mice.
4.2. Fluorescence Methods. Similar to normal breast stem
cells, CSCs have also been investigated according to
their expression of aldehyde dehydrogenase (ALDH) activ-
ity. Ginestier et al. [23] analyzed the tumorigenicity
of ALDEFLUOR-positive populations isolated from two
metastatic and two primary invasive ductal carcinomas
(three triple negative tumors—ER-negative, PR-negative,
and HER2-negative—and one ER-positive, PR-positive, and
HER2-negative tumor) that were transplanted into the
humanized cleared fat pad of immunodeﬁcient mice, imme-
diately after surgery with no previous cultivation. To test
tumorigenicity, cell sorting was performed at early passages
in animals, in order to minimize the variability introduced
by the xenotransplant model. ALDEFLUOR-positive cells
represented 3% to 10% of the total cell population, and
500 positive cells were able to generate a tumor in as
few as 40 days. Signiﬁcantly, the concomitant presence of
the ALDEFLUOR-positive phenotype and of the previously
described breast CSC phenotype (CD44+/CD24
−/low)w a s
observed in a small cell fraction of the three triple-negative
tumors (range 0.08–1.16%), whereas tumor cells generated
from one metastatic tumor (pleural eﬀusion) showed a
high percentage of overlapping cell fraction (1.16%) that
gave rise to outgrowth from as few as 20 cells. Con-
versely, ALDEFLUOR-negative cells, though bearing the
CD44+/CD24
−/low phenotype, were not tumorigenic, even
when 50000cells/fat pad were implanted. This suggests
that the concomitant presence of ALDEFLUOR-positive and
CD44+/CD24
−/low phenotypes may characterize progeni-
tor cells with proliferative potential. When assessing the
potential use of ALDH1 to detect malignant mammary
stem/progenitor cells in situ on breast cancer tissue sections,
Ginestier et al. [23] found that ALDH1 expression correlated
with the histoclinical parameters, suggesting the use of this
marker as a powerful predictor of poor clinical outcome.
So far, therefore, the ALDEFLUOR assay, overcoming the
limited availability of CSC-speciﬁc surface markers, seems to
represent the pivotal tool for the isolation of cell populations
withhightumor-initiatingcapabilityorcellpopulationswith
stem-likepropertiesinnormaltissue,allowingtheidentiﬁca-
tion of stem/progenitor cells involved in normal mammary
development and may be in tumor transformation.
As regards the use of Hoechst 33342 to detect the side
population and to identify CSCs, thus bypassing the lack of
universally accepted surface-antigen markers, several limi-
tations are emerging in addition to the technical criticisms
described for the methods of normal mammary stem cell
isolation; they include the low cell recovery from tumor
tissue that does not reﬂect the entire cohort of cancer cells,
andthetoxicityofthedyethatprecludesitsuseforfunctional
CSC assays in vitro and in vivo [50].
4.3. Self-Renewal Pathways. Since another trait shared by
normal stem cells and CSCs is the ability to self-renew,
the deregulation of key pathways involved in such a pivotal
cellular function has been presumed to be implicated in
breast carcinogenesis and more thoroughly investigated.
Experimental evidence indicates that carcinogenesis in the
mammary gland, and in other solid organs, might result in
thetransformationofstemand/orprogenitorcellsbecauseof
the deregulation of self-renewal pathways, including Notch,
Wnt, Hedgehog, and the transcription factor Bmi1 [51]a n d
suggests that the targeting of self-renewal pathways might
provide a speciﬁc approach to eradicate CSCs [52]. However,Journal of Oncology 7
in developing and testing compounds against putative CSCs,
several uncertainties must be faced and elucidated, ﬁrst of all
the possible instability of CSCs that could hamper speciﬁc
cell targeting.
5.LimitstotheXenograft Approach
There are several limitations to the use of xenograft assays as
proof of “stemness”. The most relevant is that tumor growth
and stem cell phenotype are not only determined by intrinsic
characteristics of tumor cells but are also inﬂuenced by the
microenvironment in which cells grow. In this respect, the
heterogeneity found in animal experimental models does
not prove that normal or malignant stem cells undergo
asymmetric division but just reﬂects a change in cell surface
antigen expression induced by environmental conditions.
Simply injecting tumor cells into mice without measuring
the time of latency required to form a palpable tumor
mass may induce to draw wrong conclusions about their
absolute tumorigenic potential, which may be inﬂuenced
by environmental conditions. Another important limitation
to CSC investigation is the eﬃciency of thein vivo model
used. It is well known that xenograft is less eﬃcient than
syngeneic transplant because of the presence of animal
growth factors that could interact with their equivalent
human receptors and provide confounding stimuli for the
transplanted human stem/progenitor cells. In a recent paper,
Kelly et al. [53], challenging the CSC hypothesis, proposed
that xenograft may select a dominant clone capable of
surviving and maintaining tumor outgrowth in a foreign
environment, and stressed the importance of performing a
tumorigenic assay using cells sorted from the patient’s tumor
to avoid cell variability and the selection of a dominant
cell subpopulation, after several serial passages in animals,
whereas the majority of cells die owing to the lack of
appropriate supporting factors.
As regards the mammary gland, in order to study human
breast carcinogenesis, it is central to establish a model
system that more accurately recapitulates normal breast
epithelial development in rodents. For cancer cells, such a
system should also correlate with the clinical behavior of the
source tumor in patients. However, the inability of human
breast epithelial cells to colonize mouse mammary fat pads
represents a constant problem.
The importance of both species- and tissue-speciﬁc
inﬂuenceshasbeenhighlightedinthestudiesbyKuperwasser
et al. [54], which indicated that, although outgrowths can
be generated in the murine humanized mammary fat pads,
the repopulating frequency by normal breast stem cells
remains relatively low. This suggests that the expression of
some markers of the inoculated cells could be inﬂuenced by
circulating or locally produced animal-speciﬁc factors. For
example, estrogen has been found to profoundly aﬀect the
growth of ER-negative breast cancer cells because circulating
mouse estrogens led to recruitment of bone marrow-derived
stromal cells and promoted the growth of tumors in virgin
mice [55].
However, despite these limitations, xenograft models still
represent an essential tool for in vivo carcinogenesis studies.
Meanwhile, the great challenge in stem cell investigation will
be the standardization of an orthotopic model in which
the whole tumor bulk could arise from a single deﬁnitively
characterized human breast CSC.
6. IssuesConcerning Established Breast
CancerCellLines
Despite the intriguing results so far obtained, the use of
established breast cancer cell lines as experimental models
to collect data regarding CSCs is not without pitfalls, the
main one being the attempt to apply stem-cell concepts to
breastcelllines.Establishedcelllines,infact,arecultivatedin
artiﬁcial conditions (depending on the experimental model)
for many generations, with the risk that the unavoidable
selection induced by the serum media blurs the distinc-
tion between tumorigenic and nontumorigenic clones. For
example, in vitro culture conditions, such as growth with or
without serum medium, could contribute to the functional
diﬀerences found between non-CSCs and CSCs, including a
diverse proliferative activity.
It is unlikely that the so-called “cancer stem cells” derived
from established cell lines are the stem cells that make up
a tumor. It is more likely that the “stem cell component”
indicated as responsible for maintaining the line is in reality
only a subpopulation of cells having a high-proliferative rate
and being able to form clonal aggregates in the presence of
additional techniques, for example, retroviral marking [16].
Therefore, extending the CSC concept to cell lines could
be misleading as is the case with the results reported by
Sheridan et al. [56]. In a series of established breast cancer
cell lines (MDA-MB-231, TMD-436, Hs578T, SUM1315,
HBL-100, and MDA-MB-468), the authors observed a high
percentage (>30%) of CD44+/CD24
−/low cells which were
highly eﬃcientin initiating a tumor in experimental settings,
and concluded that those cell lines were composed mainly of
cancer stem cells. However, since the CD44+/CD24
−/low phe-
notype has been shown to be insuﬃcient to confer stem-like
properties [23], such an enrichment in CD44+/CD24
−/low
phenotype in established cell lines could be hypothesized
to be a puriﬁcation marker without functional implica-
tions. Therefore, it is crucial to demonstrate that such a
subpopulation, contained in established breast cancer cell
lines and displaying a putative stem-like phenotype, has
the real functional characteristics of CSCs: self-renewal and
diﬀerentiation capability. Awaiting these conﬁrmations as
well as more standardized protocols for the isolation and
expansion of CSCs from tissue, the established breast cancer
cell line model still remains a useful experimental tool to
test drugs, radioresistance, and antibodies against the surface
markers associated with the putative stem-like phenotype.
7.MicroenvironmentandStemCellNiche
Despite the extensive use of the in vivo model, in which
human tumor cells are injected into immunodeﬁcient mice,
signiﬁcant challenges are pending in experimental settings
with CSCs, mostly related to the biological and technical8 Journal of Oncology
complexities associated with identifying, quantifying, and
longitudinally monitoring CSCs in a complex in vivo envi-
ronment. In particular, as already mentioned, xenograft may
fail to reveal possible tumor growth-sustaining cells because
the heterologous microenvironment precludes essential
interactions with support cells. As recently shown in an
elegant study by Naumov et al. [57], many established
humantumorcelllines,whichhadpreviouslybeendescribed
as “nontumorigenic” (including the breast cancer cell line
MDA-MB-436), were potentially tumorigenic but dormant.
In fact, when these cells were injected into animals and
allowed to grow for a much longer period of time than a
normal tumor growth assay (up to 12 months), spontaneous
tumors eventuallybegan to develop after an initial dormancy
period and a switch to an angiogenic phenotype. Therefore,
this study provides a conceptual framework to approach the
problem that a supportive microenvironment is required for
tumor outgrowth in CSCs-involving studies.
In adults, normal stem cells reside in a physiologically
unique microenvironment called stem cell niche. This niche,
mainly composed of ﬁbroblasts and myoepithelial cells,
provides a physical anchoring site for stem cells via adhesion
molecules linking the stem cells to the extracellular matrix.
Support cells act as a hub in orientating dividing stem cells
to hold one daughter cell in the niche, while the other one
exits the niche and undergoes transit ampliﬁcation followed
by diﬀerentiation [58, 59]. Under normal physiological
conditions,thenicheprovidesﬁnecontrolovercellprolifera-
tion, typically balancing proliferation and apoptosis through
paracrine factors, so that the stem cell population remains
undiﬀerentiated and maintains a constant size [60, 61]. The
eﬀectors mediating heterotypic cell interactions within the
niche include a number of soluble factors and cell surface
receptors. Interestingly, some of these molecules, including
Wnt, Notch, TGF-β, bone morphogenetic proteins (BMPs),
andothers[62–65],areknowntobeinvolvedintumordevel-
opment, and emerging data support the idea that a “cancer
stem cell niche” could also exist, and that interactions with
such a tumor niche may sustain a self-renewing population
oftumorcells[66].Alterationsaﬀectingstromalcells,suchas
local modiﬁcations of tissue homeostasis induced by chronic
inﬂammation, have been shown to promote formation of
epithelial tumors, and very recent papers have described the
generation of pluripotent stem cells from ﬁbroblasts. This
evidence supports the possibility that cancer may arise from
just a few mutations in resident tissue stem/progenitor cells
or even diﬀerentiated cells leading to a stem-like phenotype
[67, 68]. Indeed, if signaling pathways are dysregulated,
the niche may be converted into a microenvironment that
favorsuncontrolledproliferationandexpansionofanaltered
stem cell population. Similarly, a cancer stem cell could be
hypothesized to remain dormant in a metastatic site until
activated by abnormal signaling from the microenvironment
[66].
Currently, evidence of an anatomically and/or physi-
ologically specialized environment that constitutes a true
CSC niche is scarce, and the identity of a stem cell niche
within the mouse mammary gland has not been deﬁned.
Conversely, a putative stem cell niche which gives rise to
at least three lineage-restricted cell types outside the stem
cell zone has been identiﬁed in the adult human breast
[28]. The most likely location of the niche in the mature
gland could be the ducts, where in situ analysis identiﬁed
a narrow region of quiescent cells that were stained for
putative stem cell markers including chondroitin sulphate,
K6a, CK15, and SSEA-4 [69]. However, the data published
so far do not exclude the possible existence of other niches
or models of niche. In particular, the model of the estrogen-
driven stem cell niche consists of three diﬀerent cell types:
the ER-positive sensor cells, the EGFR-positive stromal cells,
and the ER-negative stem cells. All of them could remain
quiescentuntiltheyareswitchedonbyestrogens.Inresponse
to estrogens, the ER-positive sensor cells synthesize and
secrete amphiregulin that activates EGFR-positive stromal
cells which in turn activate ER-negative stem cells [70],
although the identity of the stromal factors interacting with
the epithelial components of the stem cell niche remains
to be revealed. In addition, the similarities between stem
cell niches in diﬀerent tissues remain poorly understood, in
particular whether tissue-speciﬁc stem cells can be regulated
by stem cell niches in other organs or whether vice versa
ectopic mesenchymal stem cells may colonize a breast niche
and inﬂuence its behavior. Studies by Hochedlinger et al.
[71] support the notion that a malignant genome can be
reprogrammed to exhibit a normal-like phenotype when
transferred into a new biological context, whereas Blanpain
et al. [72] have reported that epithelial stem cells are able to
generate their own microenvironment. Tumor cells also have
thewell-establishedabilitytointeractwiththeirsurrounding
environment and to inﬂuence it profoundly; examples
are neoangiogenesis, recruitment of immune cells, and
modiﬁcation of tissue architecture. All these ﬁndings have
important and provocative implications for understanding
metastatic growth in secondary sites.
8.CSCsandMetastasis
Since the majority of breast cancer deaths occur as a result of
metastatic disease rather than from the eﬀects of the primary
tumor, one of the biggest challenges is the identiﬁcation,
as early as possible, of patients harboring metastatic cells.
In fact, the persistence of disease at a low or undetectable
level (the so-called “minimal residual disease”) is a common
feature of breast cancer as supported by autoptic ﬁndings
[73] as well as by the accumulating evidence that breast
cancer patients, even with no indication of metastatic spread
by current clinical parameters, have individual tumor cells
in their blood [74, 75]. Several studies have shown that
detection of isolated tumor cells in the bone marrow is
an independent prognostic factor. However, even though
approximately 30% of breast cancer patients may have
micrometastatic disease in their bone marrow at the onset,
only 30–50% of them will go on to develop clinically evident
metastases within 5 years [76, 77].
The presence of such cells in the bone marrow is
particularly interesting since bone represents one of the
most common sites for breast cancer metastasis, togetherJournal of Oncology 9
with regional lymph nodes, lung, liver, and brain, all of
which may represent putative nichesfor disseminating tumor
cells according to the hypothesis that cancer cells can arrest
and grow in favorite metastatic sites. This “seed and soil”
theory, ﬁrst proposed in 1889 by Paget [78], predicts that
a cancer cell (the “seed”) can survive in and colonize only
secondary sites (the “soil”) that produce growth factors
capable of signiﬁcantly inﬂuencing cell behavior [79, 80],
and has largely withstood the test of time [81]. In the case
of breast cancer, disseminated carcinoma cells are detectable
in the bone marrow [82], and recent ﬁndings indicate that
most cancer cells found in the bone marrow have a breast
CSC phenotype [83].
However, recent experimental observations demon-
strated a direct involvement of the bone marrow-derived
cells in the development of human epithelial tumors,
suggesting that CSCs may originate from bone marrow-
derived cells [84]. Furthermore, a very recent paper from
Mylona et al. [85] indicated that, in clinical breast cancer
tissues,theCD44+/CD24
−/low phenotype(i.e.,thephenotype
experimentally associated with stemness) had no signiﬁcant
correlation with clinical outcome. This is in agreement with
a previous paper by Abraham et al. [86] that found no
correlationbetweenCD44+/CD24
−/low tumorcellprevalence
and tumor progression, in terms of event-free and overall
survival. Conversely and quite surprisingly, the prevalence
of CD44
−/CD24+ tumor cells was found to exert an
unfavorable impact on patients’ relapse-free and overall
survival. This suggests that, although CD44+/CD24
−/low
breast tumor cells may be highly eﬃcient in initiating
tumors in animal experimental models, in patients, these
cells could be associated with the development of distant
metastasis, particularly bone metastases, rather than with
clinical outcome. Therefore, CD44+/CD24
−/low tumor cells
could be a subclass of tumorigenic cells characterized by a
great metastatic potential, maybe due to the role of CD44 as
a homing receptor for distant tissue compartments.
9. ClinicalImplications of CSCParadigm
andFutureDirections
The hypothesis that only CSCs are capable of reinitiating
growth to form metastases in distant sites has fundamental
clinical implications in terms of both prognosis and therapy
since it provides an explanation of the limits to many current
breast cancer treatments [87, 88]. In fact, the main goal of
the current therapeutic strategies is represented by the “gold
standard” of tumor shrinkage. However, if a tumor is main-
tainedbyasmallsubpopulationofCSCsthatisconstitutively
resistanttotherapeuticagents,tumorshrinkageresultsinthe
selectivekillingofthemorediﬀerentiated,“nontumorigenic”
cells that make up the bulk of the tumor, while leaving
cancer stem cells viable and able to continue to maintain
and/or reinitiate tumor growth on a metastatic site. Thus,
current therapies fail to account for potential molecular and
proliferative diﬀerences in the various subpopulations of
tumor cells, and may be ineﬀective on the more aggressive
and dangerous subgroup that constituted by CSCs. Since
CSCs may constitute metastasis precursor cells, as suggested
by the detection of disseminated tumor cells with a breast
CSC phenotype in the bone marrow of breast cancer patients
[83], it is of paramount importance to develop reliable
diagnostic tools through the identiﬁcation of additional and
more speciﬁc markers for CSCs or even for niche cells,
although this could be a diﬃcult task due to the complexity
of niche composition [89]. Diﬃcult but not impossible,
since recently Calabrese et al. [90]w e r ea b l et ov i s u a l i z e
brain CSCs surviving in a vascular niche that secretes factors
which promote their long-term growth and self-renewal. In
addition, innovative technologies, using sensitive imaging
techniques, have recently permitted real-time monitoring
of CSC presence and viability as well as analysis of the
angiogenic switch [91]. However, although this imaging
technique can be extremely valuable in order to achieve
a greater understanding of the biology of CSCs and their
relationship with the stromal compartment, it cannot be
used, at least at present, for intravital monitoring of such
elusive cells in patients. Conversely, more clinically relevant
imaging techniques, such as high-resolution magnetic res-
onance imaging (MRI) [92] and three-dimensional high-
frequency ultrasound [93], are currently being developed for
the study of CSCs in preclinical models. These techniques
look promising for future clinical applications to determine
prognosis, monitor therapeutic eﬃcacy, and possibly aﬀect
therapies.
In addition to its impact on diagnosis and prognosis,
the CSC hypothesis also has signiﬁcant implications for the
therapy of breast cancer. Since current therapies do not
target the tumor-initiating cells eﬀectively, as implied by
the large number of patients who relapse after adjuvant
chemotherapeutic and/or hormonal treatment [94], there
is a need for therapeutic agents speciﬁcally directed against
CSCs. These speciﬁc agents could be added to conventional
cytotoxic drugs, designed to kill actively dividing cells, and
be able to eradicate the metastatic disease. Thus, they would
turn cancer, if detected at early stage, into a curable disease
limited to the primary organ. Although we still know too
little about the molecular features distinguishing CSCs from
the bulk of tumor cells to develop a “smart drug”, the
signiﬁcant advances in the ﬁeld indicate that CSCs could
soon represent a really useful target.
10. Conclusions
Recent ﬁndings in breast biology have provided support
for the CSC hypothesis, but researchers still face many
challenges. First, attention should be paid to the accuracy
of experimental methods for the isolation and propagation
of CSCs derived from clinical samples, with a particular
emphasis on cell culture environment (substrate, atmo-
sphere, and medium) that has a critical role in standardizing
the culture conditions for breast cancer progression studies
[49]. Secondly, more accurate techniques should be used
for the sphere formation assay, so as to determine a self-
renewing capability suﬃcient to classify a cancer cell as a
cancer stem cell, and to avoid conﬂicting results obtained
by diﬀerent groups. Moreover, it is necessary to pursue the10 Journal of Oncology
clinical demonstration that CSCs can be used as a prog-
nostic indicator of disease progression and to identify the
mechanisms by which CSCs escape conventional therapies
in order to develop new speciﬁc therapeutic approaches.
Finally, there is the need to ﬁnd the deﬁnitive evidence
of the existence of CSCs and to identify the stroma-
related factors that inﬂuence the development and spread
of CSCs. Since CSCs have not yet been fully deﬁned, their
existence in breast cancer cannot conclusively be proven,
and competitive hypotheses, which may explain some of the
puzzling features of certain tumor cell populations, should
betakenintoaccount.Themostexcitingofthesecompetitive
hypotheses implies the reversible epithelial-to-mesenchymal
transition, the developmental process in which epithelial
cells acquire the migratory properties of mesenchymal cells.
As shown in a very recent paper [95], the induction of
the epithelial-mesenchymal transition could stimulate breast
cells to adopt characteristics of stem cells. This suggests that
CSCs are not distinct entities but rather tumor cells that
transiently acquire stem cell-like properties as a consequence
of an epithelial-mesenchymal transition. Undoubtedly, such
a link between epithelial-mesenchymal transition and stem
cell phenotype further fuels the debated question about
the existence of CSCs and holds a number of interesting
implications for the biology of epithelial cells, including the
possibility that the stem cells of certain epithelial organs such
as mammary glands may acquire many of the attributes of
the mesenchymal cell state that confer them an increased
tumorigenic potential.
The advent of new technologies, including gene expres-
sion proﬁling and proteomics, and the ability to apply them
t os m a l ln u m b e r so fc e l l sw i l lp r o b a b l yh e l pt os o l v es u c h
open questions.
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